Loading
Everything OnCo dates to 1994: 50 entries, 15 landmarks, 8 journals founded, 7 papers listed on people's pages and 6 companies founded. Each line links to the record it was read from, so the year is a view of the corpus rather than a second copy of it.
50 dated entries in OnCo fall in 1994: 15 landmarks, 8 journals founded, 7 papers listed on people's pages, 6 companies founded, 4 approvals, 4 papers, 4 technologies, 1 law or regulation and 1 regulatory event.
Of those, 1 to the day and 49 to the year only. Most of the corpus dates a fact to the year, because that is what the source it was read from gives; regulatory events and the readout calendar are the parts that carry a full date.
Everything on this page is generated from the other records. It holds no fact of its own, and it changes when they do.
The approvals rows on treatment records: region, year and indication.
ALL (pegaspargase, hypersensitivity to native); first line 2006
First FDG NDA (neurology and cardiology indications)
Dry mouth caused by radiotherapy for head and neck cancer
Advanced NSCLC as single agent or with cisplatin
The regulatory events on treatment records: designations, filings, decisions, label changes and withdrawals, most of them carrying a full date.
Metastatic breast cancer
The statutes, regulations, guidance and court rulings in the law index, dated to the year the instrument was made.
International, treaty.
The publication year on key paper records.
Lapidot T, Sirard C, Vormoor J, et al. Nature.
Darnell JE Jr, Kerr IM, Stark GR. Science.
Clark J, Rocques PJ, Crew AJ, et al. Nature Genetics.
Kuznetsov VA, Makalkin IA, Taylor MA, et al. Bulletin of mathematical biology.
The history entries editors wrote on cancer records: the dated turning points of each disease.
Neuroendocrine tumours. First SSTR imaging; later replaced by PET.
Peripheral T-cell lymphomas (including cutaneous T-cell lymphoma). NPM-ALK identified by Morris et al.; ALK-positive ALCL becomes the good-prognosis PTCL.
Ovarian cancer. BRCA2 in 1995; germline testing enters clinical practice over the next decade.
BRCA or PALB2-mutant pancreatic ductal adenocarcinoma
Early cervical cancer and fertility-sparing surgery
Post-transplant lymphoproliferative disorder (PTLD). Rooney, Heslop and colleagues (Lancet 1995) after stem cell transplant.
Leiomyosarcoma
Penile cancer. Horenblas and colleagues (Netherlands Cancer Institute) introduce lymphatic mapping.
Localised penile cancer (organ-confined, node-negative)
Ampullary cancer (ampulla of Vater). Kimura and colleagues link histological type to prognosis.
Kaposi sarcoma
Salivary gland cancers
Localised prostate cancer, very low and low risk
Nodular lymphocyte-predominant Hodgkin lymphoma (nodular lymphocyte-predominant B-cell lymphoma)
Synovial sarcoma
The since year on technology records: first use in humans or first approval, as the record states it.
First use in humans or first approval, as the technology record states it.
First use in humans or first approval, as the technology record states it.
First use in humans or first approval, as the technology record states it.
First use in humans or first approval, as the technology record states it.
The founded year on company records.
Petah Tikva
Melbourne
New York, NY
Paris
Planegg
Shanghai
The founded year on journal records.
Springer
Springer
SAGE Publishing
Springer Nature
MDPI
Bioscientifica
Springer (Springer Nature)
Spandidos Publications
The selected publications each biography lists, which is a reading of that person rather than a reading of the year.
European Journal of Cancer
Nature Genetics
Molecular and Cellular Biology
Nature Genetics
Journal of Virology
Annals of Surgery
Cancer Research